Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics


Ligand Pharmaceuticals Incorporated (LGND)

Today's Latest Price: $85.92 USD

1.49 (-1.70%)

Updated Nov 27 1:00pm

Add LGND to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

LGND Stock Summary

  • Price to trailing twelve month operating cash flow for LGND is currently 29.6, higher than 85.74% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of -28.46%, Ligand Pharmaceuticals Inc's debt growth rate surpasses only 11.04% of about US stocks.
  • Ligand Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 25.74%, greater than the shareholder yield of 91.09% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Ligand Pharmaceuticals Inc, a group of peers worth examining would be KMPH, AKTS, AXDX, QTWO, and GNMK.
  • Visit LGND's SEC page to see the company's official filings. To visit the company's web site, go to www.ligand.com.

LGND Stock Price Chart Interactive Chart >

Price chart for LGND

LGND Price/Volume Stats

Current price $85.92 52-week high $127.80
Prev. close $87.41 52-week low $57.24
Day low $85.03 Volume 175,300
Day high $89.29 Avg. volume 380,983
50-day MA $90.11 Dividend yield N/A
200-day MA $99.54 Market Cap 1.38B

Ligand Pharmaceuticals Incorporated (LGND) Company Bio


Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.

LGND Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$85.92$28.44 -66%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Ligand Pharmaceuticals Inc. To summarize, we found that Ligand Pharmaceuticals Inc ranked in the 24th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for LGND, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 0.26 -- which is good for besting just 24.31% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • Ligand Pharmaceuticals Inc's weighted average cost of capital (WACC) is 11%; for context, that number is higher than 77.82% of tickers in our DCF set.
  • Ligand Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-66%
1%-66%
2%-66%
3%-65%
4%-65%
5%-65%

ABC, SNN, RMD, VIVO, and A can be thought of as valuation peers to LGND, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


LGND Latest News Stream


Event/Time News Detail
Loading, please wait...

LGND Latest Social Stream


Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about Ligand Pharmaceuticals Inc that investors may wish to consider to help them evaluate LGND as an investment opportunity.

Global Restless Leg Syndrome Market Analysis & Future Growth Analysis Report By Product Type, Industry Application And Future Technology 2026||Ligand Pharmaceuticals Incorporated, Jazz Pharmaceuticals, Inc, Hisamitsu Pharmaceutical Co., Inc, Intas Pharmac

Data bridge Market research provides a report in which the Restless Leg Syndrome market drivers and regulations are derived from a famous SWOT analysis technique. We’ve taken up their organization profiles to really understand those key gamers and types.

OpenPR | September 28, 2020

Ligand forecasts big jump in Captisol material sales in 2021

Ligand Pharmaceuticals ([[LGND]] +5.0%) expects Captisol material sales of ~$200M in 2021 compared to its 2020 full-year expectation of $90M.The company said “recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and...

Seeking Alpha | September 23, 2020

Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and position Captisol for major growth. Significant new clinical and regulatory developments with Evomela and Kyprolis, among other drugs, are reinforcing the role the proprietary technology serves in enabling important

Business Wire | September 23, 2020

Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology platform. Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5 million in cash plus non-transferable contingent value rights (CVRs). In addition, Ligand will invest $2.5 million in a new company, Minotaur Therapeutics, which will

Business Wire | September 10, 2020

Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain

Business Wire | August 31, 2020

Read More 'LGND' Stories Here

LGND Price Returns

1-mo 4.21%
3-mo -15.76%
6-mo -22.43%
1-year -23.96%
3-year -34.84%
5-year -20.82%
YTD -17.61%
2019 -23.15%
2018 -0.90%
2017 34.76%
2016 -6.28%
2015 103.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9083 seconds.